Literature DB >> 28550030

Debunking the Delusion That Precision Oncology Is an Illusion.

Vivek Subbiah1, Razelle Kurzrock2.   

Abstract

Mesh：

Year:  2017        PMID： 28550030      PMCID： PMC5553950          DOI： 10.1634/theoncologist.2017-0040

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  20 in total

1.  Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

2.  Exceptional responders: in search of the science behind the miracle cancer cures.

Authors:  Ishwaria Mohan Subbiah; Vivek Subbiah
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

3.  Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

4.  Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

Authors:  Vivek Subbiah; David S Hong; Funda Meric-Bernstam
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-25       Impact factor: 11.205

5.  Perspective: The precision-oncology illusion.

Authors:  Vinay Prasad
Journal:  Nature       Date:  2016-09-08       Impact factor: 49.962

Review 6.  Patient-centric trials for therapeutic development in precision oncology.

Authors:  Andrew V Biankin; Steven Piantadosi; Simon J Hollingsworth
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

7.  Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors:  Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

8.  STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Authors:  Vivek Subbiah; Caitlin McMahon; Shreyaskumar Patel; Ralph Zinner; Elvio G Silva; Julia A Elvin; Ishwaria M Subbiah; Chimela Ohaji; Dhakshina Moorthy Ganeshan; Deepa Anand; Charles F Levenback; Jenny Berry; Tim Brennan; Juliann Chmielecki; Zachary R Chalmers; John Mayfield; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2015-06-11       Impact factor: 17.388

9.  Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Authors:  Vivek Subbiah; Robert E Brown; Jamie Buryanek; Jonathan Trent; Avi Ashkenazi; Roy Herbst; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-08-20       Impact factor: 6.009

10.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.

Authors:  Vivek Subbiah; Shannon N Westin; Kai Wang; Dejka Araujo; Wei-Lien Wang; Vincent A Miller; Jeffrey S Ross; Phillip J Stephens; Gary A Palmer; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2014-01-14       Impact factor: 17.388
View more
  7 in total

Review 1.  A role for microfluidic systems in precision medicine.

Authors:  Jose M Ayuso; María Virumbrales-Muñoz; Joshua M Lang; David J Beebe
Journal:  Nat Commun       Date:  2022-06-02       Impact factor: 17.694

Review 2.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

3.  "My Research Is Their Business, but I'm Not Their Business": Patient and Clinician Perspectives on Commercialization of Precision Oncology Data.

Authors:  Kayte Spector-Bagdady; Chris D Krenz; Collin Brummel; J Chad Brenner; Carol R Bradford; Andrew G Shuman
Journal:  Oncologist       Date:  2020-03-13       Impact factor: 5.837

4.  Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Authors:  Zahi I Mitri; Swapnil Parmar; Brett Johnson; Annette Kolodzie; Jamie M Keck; Max Morris; Alexander R Guimaraes; Brooke R Beckett; Uma Borate; Charles D Lopez; Kathleen A Kemmer; Joshi J Alumkal; Tomasz M Beer; Christopher L Corless; Gordon B Mills; Joe W Gray; Raymond C Bergan
Journal:  J Transl Med       Date:  2018-12-14       Impact factor: 5.531

Review 5.  Value-based genomics.

Authors:  Jun Gong; Kathy Pan; Marwan Fakih; Sumanta Pal; Ravi Salgia
Journal:  Oncotarget       Date:  2018-01-30

6.  Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis.

Authors:  Audrey Tran; Quiana Klossner; Tyler Crain; Vinay Prasad
Journal:  BMJ Open       Date:  2020-06-07       Impact factor: 2.692

7.  High Expression of the Long Noncoding RNA SNHG15 in Cancer Tissue Samples Predicts an Unfavorable Prognosis of Cancer Patients: A Meta-Analysis.

Authors:  Cheng Zhang; Yang Ke; Xin Liu; Xinghong Wang; Yuehua Li; Jian Zhou; Heng Zhang; Lin Wang
Journal:  J Oncol       Date:  2020-07-15       Impact factor: 4.375
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.